Respiratory Syncytial Virus (RSV) News and Research

RSS
Respiratory syncytial virus (RSV) causes mild, cold-like symptoms in adults and older children. However, it can cause serious problems in young babies, including pneumonia and severe breathing problems. In rare cases it can lead to death. Premature babies and those with other health problems have the highest risk. A child with RSV may have a fever, stuffy nose, cough and trouble breathing. Tests can tell if your child has the virus.
Extremely contagious RSV virus can lead to serious illness in young children

Extremely contagious RSV virus can lead to serious illness in young children

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

RSV medication from specialty pharmacies increases likelihood of children receiving recommended doses

RSV medication from specialty pharmacies increases likelihood of children receiving recommended doses

MicroDose initiates MDT-637 Phase 1 trial in respiratory syncytial virus

MicroDose initiates MDT-637 Phase 1 trial in respiratory syncytial virus

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

Kineta's next generation antiviral program receives $2.8 million NIH SBIR grant

Kineta's next generation antiviral program receives $2.8 million NIH SBIR grant

Study finds very low rates of pertussis in children with cough

Study finds very low rates of pertussis in children with cough

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

Alnylam second quarter revenue decreases to $20.6 million

Alnylam second quarter revenue decreases to $20.6 million

Serious RSV infections may occur in previously healthy infants and children

Serious RSV infections may occur in previously healthy infants and children

Novavax first quarter net loss decreases to $7.5 million

Novavax first quarter net loss decreases to $7.5 million

MedImmune abstracts on influenza and RSV to be presented at PAS meeting

MedImmune abstracts on influenza and RSV to be presented at PAS meeting

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

February is again peak time for influenza across the nation

February is again peak time for influenza across the nation

Immunization with VLP vaccine results in functional, protective immune responses against RSV

Immunization with VLP vaccine results in functional, protective immune responses against RSV

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Encouraging GenVec RSV vaccine program data presented at International Respiratory Syncytial Virus Symposium

Encouraging GenVec RSV vaccine program data presented at International Respiratory Syncytial Virus Symposium

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam third quarter revenue increases from $24.2 million to $27.7 million